Royalty Pharma buys cliramitug royalty stake from Neurimmune for up to $425 million
PUBT · 1d ago
Share
Listen to the news
- Royalty Pharma acquired part of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.
- Deal grants a 3% to 4% royalty on worldwide net sales of cliramitug, a Phase 3 antibody for ATTR-CM.
- Another $125 million cash payment is due in Q1 2027; remaining $175 million tied to clinical and regulatory milestones.
- Phase 3 DepleTTR-CM trial results are expected in 2028; AstraZeneca has guided to $3 billion to $5 billion peak sales.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220705PRIMZONEFULLFEED9766267) on July 22, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved